Nephrogenic systemic fibrosis: an overview.
In 1997, a new fibrosing skin disorder became apparent among patients with renal disease. Nephrogenic systemic fibrosis, as this disorder has come to be known, has recently been tied to the administration of contrast agents containing gadolinium. This overview examines the discovery and elucidation of the major research accomplishments to date. It was presented as the keynote address at the First Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and MRI Contrast, conducted at Yale University on May 4, 2007.
Cowper
Shawn E
SE
Yale University Dermatopathology Service, New Haven, Connecticut 06520, USA. shawn.cowper@yale.edu
D000138:Acidosis / Q000150:complications; D000818:Animals; D003287:Contrast Media / Q000009:adverse effects*; D005355:Fibrosis / Q000139:chemically induced / Q000473:pathology; D005682:Gadolinium / Q000009:adverse effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008279:Magnetic Resonance Imaging; D051437:Renal Insufficiency / Q000150:complications*; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
D003287:Contrast Media; D005682:Gadolinium